Kim Hae Su, Lee Ji Yun, Lee Su Jin, Lim Ho Yeong, Sung Hyun Hwan, Jeon Hwang Gyun, Jeong Byong Chang, Seo Seong Il, Jeon Seong Soo, Lee Hyun Moo, Choi Han-Yong, Park Se Hoon
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro Gangnam-gu, Seoul, 135-710, South Korea.
Department of Hematology-Oncology, Department of Medicine, Veterans Health Service Medical Center, Seoul, South Korea.
BMC Urol. 2017 Aug 22;17(1):63. doi: 10.1186/s12894-017-0253-z.
The aim of this retrospective study was to evaluate the clinical outcomes of reduced dose, biweekly docetaxel chemotherapy for Korean patients with castrate-resistant prostate cancer (CRPC).
We retrospectively reviewed the medical records of 48 patients with metastatic CRPC who were treated with a biweekly regimen (intravenous docetaxel 40 mg/m on day 1 plus prednisolone 5 mg twice daily) between 2012 and 2015 at Samsung Medical Center (Seoul, Korea). Prior to the adoption of a biweekly regimen in Oct 2013, our institutional standard chemotherapy was docetaxel 75 mg/m every 3 weeks for patients with CRPC (n = 24). After Oct 2013, all chemotherapy-naïve patients with CRPC received a 40 mg/m biweekly regimen (n = 24). The primary end point was a PSA response, defined as a greater than 50% decline in PSA level from baseline.
The baseline characteristics of the patients in the two treatment groups were similar. The most common cause of treatment discontinuation was disease progression, which was exhibited by 17 patients (71%) in the 3-weekly group and 20 (75%) in the biweekly group. PSA responses were observed in 12 (50%) and 11 (46%) patients in the 3-weekly and biweekly groups, respectively (p = 0.683). Time to treatment failure (TTTF, 4.5 vs 3.9 months) and time-to-progression (TTP, 5.0 vs 4.2 months) were not significantly different between the 3-weekly and biweekly groups.
Within the limitations of a retrospective study, the biweekly reduced dose docetaxel regimen was active and well-tolerated in Korean patients with metastatic CRPC.
本回顾性研究旨在评估采用降低剂量、每两周一次多西他赛化疗方案对韩国去势抵抗性前列腺癌（CRPC）患者的临床疗效。
我们回顾性分析了2012年至2015年在三星医疗中心（韩国首尔）接受每两周一次治疗方案（第1天静脉注射多西他赛40mg/m²加泼尼松龙5mg，每日两次）的48例转移性CRPC患者的病历。在2013年10月采用每两周一次的治疗方案之前，我们机构对CRPC患者（n = 24）的标准化疗方案是每3周一次多西他赛75mg/m²。2013年10月之后，所有未接受过化疗的CRPC患者均接受每两周一次40mg/m²的治疗方案（n = 24）。主要终点是PSA反应，定义为PSA水平较基线下降超过50%。
两个治疗组患者的基线特征相似。最常见的治疗中断原因是疾病进展，3周一次治疗组有17例患者（71%）出现，每两周一次治疗组有20例患者（75%）出现。3周一次治疗组和每两周一次治疗组分别有12例（50%）和11例（46%）患者出现PSA反应（p = 0.683）。3周一次治疗组和每两周一次治疗组之间的治疗失败时间（TTTF，4.5个月对3.9个月）和疾病进展时间（TTP，5.0个月对4.2个月）无显著差异。
在回顾性研究的局限性范围内，每两周一次降低剂量的多西他赛方案对韩国转移性CRPC患者具有活性且耐受性良好。
